NCT00746642

Brief Summary

Most patients with diabetes mellitus have to measure their blood glucose levels quite often, in order to maintain a proper glycemic control. Current methods of self-monitoring of blood glucose are invasive, painful, uncomfortable, and only allow occasional, from time-to-time, measurements. Real-time continuous monitoring would provide a helpful tool for improvement of glycemic control, thus decreasing the incidence of hypoglycemia and improving glucose control. The Mellitor sensor is a new concept of continue glucose monitoring device. The Mellitor device is an implantable continuous glucose monitoring sensor that is intended for detection episodes of hyperglycemia and hypoglycemia in diabetic patients, and facilitates both acute and long-term therapy adjustments. This study was design in order to evaluate glucose measurement capabilities by the Mellitor sensor that is being developed. Transudate liquid samples, withdrawn in a clinical procedure and normally immediately disposed, will be used for glucose measurement by the Mellitor sensor. Study Design This study is an ex-vivo comparative study. 20 patients will be recruited for the study, according to patients' inflow and meeting eligibility criteria. Study Goal Study objective is to evaluate the feasibility of the Mellitor Sensor technology for glucose level measurement. Study Endpoint Mellitor technology feasibility will be established by comparing Mellitor glucose measurements results, based on transudate/exudates liquid withdrawal for other medical reasons, to "gold standard, Yellow Springs" glucose analyzer, or a comparable, calibrated and approved device using the same transudate/exudates liquid. Interdevice variability should be within 10%.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for not_applicable diabetes-mellitus

Timeline
Completed

Started Oct 2009

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 3, 2008

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 4, 2008

Completed
1.1 years until next milestone

Study Start

First participant enrolled

October 1, 2009

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

May 1, 2010

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2010

Completed
Last Updated

June 4, 2009

Status Verified

June 1, 2009

Enrollment Period

7 months

First QC Date

September 3, 2008

Last Update Submit

June 2, 2009

Conditions

Keywords

glucose measurements

Outcome Measures

Primary Outcomes (1)

  • Mellitor technology feasibility will be established by comparing Mellitor glucose measurements results to "gold standard, Yellow Springs" glucose analyzer, or a comparable. Interdevice variability should be within 10%.

    during glucose measurements

Study Arms (2)

A

EXPERIMENTAL

Glucose measurements using "Mellitor" device.

Device: Mellitor device for glucose measurement

B

ACTIVE COMPARATOR

Glucose measurements conducted by using gold standard, "Yellow Springs" glucose analyzer

Device: Mellitor device for glucose measurement

Interventions

Glucose measurement using "Mellitor" device

AB

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male/Female aged 18 and up.
  • Subject was scheduled for transudate/exudate liquid withdrawal.
  • Subject able to comprehend and give informed consent for participation in this study.
  • Signed Informed Consent Form

You may not qualify if:

  • Known cognitive or psychiatric disorder.
  • Subjects with HIV.
  • Subject refuses to sign inform consent form.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hadassah Medical Organization

Jerusalem, 91120, Israel

Location

MeSH Terms

Conditions

Diabetes Mellitus

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Roi Eldor, MD

    Hadassah Medical Organization, Jerusalem

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY

Study Record Dates

First Submitted

September 3, 2008

First Posted

September 4, 2008

Study Start

October 1, 2009

Primary Completion

May 1, 2010

Study Completion

October 1, 2010

Last Updated

June 4, 2009

Record last verified: 2009-06

Locations